文献速递心脑血管急症复苏、休克与脓毒症

胺碘酮、利多卡因或安慰剂给药时间与难治性院外心脏骤停生存的关系

Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest.
PubMed 文献 · Acad Emerg Med · 2023-04-05
一句话结论初始可除颤心律的难治性院外心脏骤停患者,8分钟内给予胺碘酮较安慰剂提高入院生存、出院生存和功能生存;晚期给药无显著差异。

该研究为胺碘酮、利多卡因或安慰剂治疗院外心脏骤停随机对照试验的二次分析,纳入初始可除颤心律且在自主循环恢复前接受研究药物的患者2802例,按给药时间分为早期(<8分钟,879例,31.4%)和晚期(≥8分钟,1923例,68.6%)两组。早期组中,胺碘酮较安慰剂显著提高入院生存(62.0% vs 48.5%,p=0.001;校正OR 1.76[95%CI 1.24-2.50])、出院生存(37.1% vs 28.0%,p=0.021;OR 1.56[1.07-2.29])和功能生存(31.6% vs 23.3%,p=0.029;OR 1.55[1.04-2.32]);早期利多卡因与安慰剂无显著差异(p>0.05)。晚期组胺碘酮或利多卡因与安慰剂相比,出院结局均无显著差异(p>0.05)。提示胺碘酮的获益可能取决于给药时机,尤其应在8分钟内给予。

要点

  • 早期(<8分钟)胺碘酮较安慰剂显著提高出院生存:37.1% vs 28.0%,p=0.021,校正OR 1.56(95%CI 1.07-2.29)。
  • 早期胺碘酮较安慰剂显著提高功能生存(mRS≤3):31.6% vs 23.3%,p=0.029,校正OR 1.55(95%CI 1.04-2.32)。
  • 早期胺碘酮较安慰剂显著提高入院生存:62.0% vs 48.5%,p=0.001,校正OR 1.76(95%CI 1.24-2.50)。
  • 早期利多卡因与早期安慰剂相比,各项结局均无显著差异(p>0.05)。
  • 晚期(≥8分钟)给予胺碘酮或利多卡因,出院结局与安慰剂相比均无显著差异(p>0.05)。

适用人群与场景

  • 初始可除颤心律、在自主循环恢复前接受胺碘酮、利多卡因或安慰剂的院外心脏骤停患者。
  • 10个站点、55个急救医疗服务机构参与的双盲随机对照试验的二次分析人群。

诊断标准与关键阈值

  • 按急救医疗服务到达现场至给药时间分层:早期<8分钟,晚期≥8分钟。

处置流程与药物剂量

  • 早期(<8分钟)给予胺碘酮较安慰剂提高入院生存、出院生存和功能生存。
  • 早期(<8分钟)给予利多卡因与安慰剂相比结局无显著差异(p>0.05)。
  • 晚期(≥8分钟)给予胺碘酮或利多卡因与安慰剂相比出院结局无显著差异(p>0.05)。

研究设计与关键结果

  • 研究类型:10个站点、55个急救医疗服务机构参与的双盲随机对照试验的二次分析;纳入2802例患者,早期组879例(31.4%),晚期组1923例(68.6%)。
  • 早期组胺碘酮 vs 安慰剂:入院生存62.0% vs 48.5%(p=0.001;校正OR 1.76[95%CI 1.24-2.50]),出院生存37.1% vs 28.0%(p=0.021;校正OR 1.56[95%CI 1.07-2.29]),功能生存31.6% vs 23.3%(p=0.029;校正OR 1.55[95%CI 1.04-2.32])。
  • 早期组利多卡因 vs 安慰剂:各项结局均无显著差异(p>0.05)。
  • 晚期组胺碘酮或利多卡因 vs 安慰剂:出院结局均无显著差异(p>0.05)。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,早期给予胺碘酮(尤其8分钟内)与初始可除颤心律患者更高的入院生存、出院生存和功能生存相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Amiodarone and lidocaine have not been shown to have a clear survival benefit compared to placebo for out-of-hospital cardiac arrest (OHCA). However, randomized trials may have been impacted by delayed administration of the study drugs. We sought to evaluate how timing from emergency medical services (EMS) arrival on scene to drug administration affects the efficacy of amiodarone and lidocaine compared to placebo.

METHOD: This is a secondary analysis of the 10-site, 55-EMS-agency double-blind randomized controlled amiodarone, lidocaine, or placebo in OHCA study. We included patients with initial shockable rhythms who received the study drugs of amiodarone, lidocaine, or placebo before achieving return of spontaneous circulation. We performed logistic regression analyses evaluating survival to hospital discharge and secondary outcomes of survival to admission and functional survival (modified Rankin scale score ≤ 3). We evaluated the samples stratified by early (<8 min) and late administration groups (≥8 min). We compared outcomes for amiodarone and lidocaine compared to placebo and adjust for potential confounders.

RESULTS: There were 2802 patients meeting inclusion criteria, with 879 (31.4%) in the early (<8 min) and 1923 (68.6%) in the late (≥8 min) groups. In the early group, patients receiving amiodarone, compared to placebo, had significantly higher survival to admission (62.0% vs. 48.5%, p = 0.001; adjusted OR [95% CI] 1.76 [1.24-2.50]), survival to discharge (37.1% vs. 28.0%, p = 0.021; 1.56 [1.07-2.29]), and functional survival (31.6% vs. 23.3%, p = 0.029; 1.55 [1.04-2.32]). There were no significant differences with early lidocaine compared to early placebo (p > 0.05). Patients in the late group who received amiodarone or lidocaine had no significant differences in outcomes at discharge compared to placebo (p > 0.05).

CONCLUSIONS: The early administration of amiodarone, particularly within 8 min, is associated with greater survival to admission, survival to discharge, and functional survival compared to placebo in patients with an initial shockable rhythm.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lupton JR, Neth MR, Sahni R, et al. Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest. Acad Emerg Med. 2023. PMID: 36869657. doi:10.1111/acem.14716

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。